文献速递慢阻肺

稳定期与急性加重期COPD血嗜酸性粒细胞表型的稳定性

Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD.
PubMed 文献 · Chest · 2019-04-29

多中心观察性研究纳入210例GOLD II-IV级稳定期COPD患者共2059次访视,评估血嗜酸性粒细胞在150/300 cells/μL及2%、3%、4%界值下的持续性。结果显示无论是否急性加重或住院,使用2%、3%、4%界值时不一致率分别为77%、60%、42%,仅用两次访视分析时降至34.5%、24%、17.2%,绝对计数结果类似。结论认为血嗜酸性粒细胞在COPD病程中变异显著,单次测量可能不是ICS反应的可靠预测指标。

要点

  • 血嗜酸性粒细胞在COPD病程中变异大,单次测量难以可靠预测ICS反应。
  • 使用2%、3%、4%界值时患者间不一致率分别达77%、60%、42%。
  • 仅用两次访视分析时不一致率降至34.5%、24%、17.2%,绝对计数类似。

核心结论

  • 血嗜酸性粒细胞在COPD全病程中呈现显著变异,单次测量可能不是ICS反应的可靠预测指标。

研究设计与样本

  • 多中心观察性试验纳入稳定期COPD且GOLD气流阻塞II-IV级患者,共210例、2059次访视。
  • 入组时记录ICS治疗数据,评估血嗜酸性粒细胞在绝对界值150和300 cells/μL及百分比界值2%、3%、4%下的持续性。

主要发现

  • 评估中位7天(4;12)的嗜酸性粒细胞水平,无论是否急性加重或住院,2%、3%、4%界值的不一致率分别为77%、60%、42%。
  • 仅用两次访视分析时,不一致率分别为34.5%、24%、17.2%,使用绝对嗜酸性粒细胞值时结果类似。
  • 稳定期患者的不一致值高于轻/中度急性加重患者,因其他疾病住院者高于因COPD严重急性加重住院者。
  • 无论研究开始时是否使用ICS,不一致率均较高。

临床怎么用

  • 临床不应仅凭单次血嗜酸性粒细胞水平预测COPD患者对ICS的反应或急性加重风险。
  • 解读血嗜酸性粒细胞作为生物标志物时需考虑其随时间显著变异的特性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is controversy regarding the use of blood eosinophil levels as a biomarker of exacerbation risk and responsiveness of patients to inhaled corticosteroids (ICS). METHODS: Patients in stable COPD with Gold Initiative for Chronic Obstructive Lung Disease airflow obstruction grades II to IV were enrolled in an observational multicenter trial. Concordance was defined as blood eosinophil values persistently lower than or persistently higher than the absolute cutoff points of 150 cells/μL and 300 cells/μL, or the percentage cutoff points of 2%, 3%, and 4%. Discordance was obtained when the blood eosinophil values varied between any two visits. ICS treatment data were recorded at one time point at the inclusion of the study. RESULTS: A total of 210 patients with 2,059 visits were included in the study. Seventy percent of the patients were male, and 36% were current smokers; their average age was 67.7 ± 9.4 years, and 81% were receiving ICS at the start of the study. Assessing eosinophil levels over time (median, 7 days [4; 12]), irrespective of exacerbation or hospitalization, there was a discordance of 77%, 60%, and 42% when using the 2%, 3% and 4% cutoffs, respectively. This outcome changed to 34.5%, 24%, and 17.2% discordance when only using two visits for the analysis. The discordance was similar when using absolute eosinophil values. Patients in a stable state had higher discordant values than patients with mild/moderate exacerbations. The same was seen in patients hospitalized for other illnesses compared with patients hospitalized for severe exacerbation of COPD. Discordancy was high regardless of whether patients were taking ICS at the beginning of the study period. CONCLUSIONS: These study data suggest that blood eosinophil levels present significant variability throughout the course of COPD, and a single measurement may therefore not be a reliable predictor of ICS response.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Schumann DM, Tamm M, Kostikas K, et al. Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD. Chest. 2019. PMID: 31047957. doi:10.1016/j.chest.2019.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。